1 HOUSE RESOLUTION

- WHEREAS, Hundreds of thousands of people in the United
- 3 States, including the State of Illinois, depend on protein
- 4 therapies derived from human plasma ("plasma therapies") to
- 5 treat serious and life-threatening diseases and conditions
- 6 such as hemophilia, primary immune disorder, Alpha-1
- 7 Antitrypsin deficiency (Alpha-1), Rh Negative blood
- 8 incompatibility, shock, and burns; and
- 9 WHEREAS, Assuring the continued quality and safety of
- 10 plasma therapies is a top priority of patients, public health
- 11 authorities, and the plasma collection and fractionation
- 12 industry; and
- 13 WHEREAS, The plasma industry and its global trade
- 14 association have developed the QSEAL (Quality Standards of
- 15 Excellence Assurance and Leadership) and IQPP (International
- 16 Quality Plasma Program) standards that currently represent
- 17 the highest reasonably attainable quality and safety
- 18 standards for human source plasma used in processing of
- 19 plasma protein therapies; and
- 20 WHEREAS, These QSEAL standards include: strict criteria
- 21 for the selection of qualified donors, including the
- 22 requirements that the donor successfully pass a minimum of
- 23 two separate health screenings and two separate validated
- laboratory tests before any donation can be used; the use of
- 25 a 60-day inventory hold and the requirement that if new
- 26 information is received indicating that donor is no longer
- 27 qualified, previous donations from that donor held in
- 28 inventory are required to be destroyed; the use of
- 29 state-of-the-art Nucleic acid Amplification Technology (NAT)
- 30 to detect any potential presence of human immunodeficiency
- 31 virus (HIV), Hepatitis B Virus (HBV), and Hepatitis C virus
- 32 (HCV) and any potential presence at critical levels of

- 1 parvovirus B 19; and the requirement that plasma used to
- 2 produce plasma therapies be collected at centers that adhere
- 3 to, and are judged by, specific strict viral market
- 4 standards; and
- 5 WHEREAS, These QSEAL and IQPP standards provide an extra
- 6 margin of safety beyond federal and State regulatory
- 7 requirements for the collecting, processing, and testing of
- 8 human plasma; and
- 9 WHEREAS, These QSEAL and IQPP standards have helped drive
- 10 the adoption of enhanced and consistent safety standards for
- 11 plasma collection and processing; and
- 12 WHEREAS, It is important to further increase public
- awareness of the value of donating blood and plasma, as well
- 14 as an appreciation of the safety of plasma therapies and the
- 15 processes by which that safety is assured; therefore, be it
- 16 RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE
- 17 NINETY-THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that
- 18 the IQPP and QSEAL certification programs are important ways
- 19 to ensure that only the highest quality plasma is collected
- 20 and used for processing of plasma-derived therapeutic
- 21 proteins; and be it further
- 22 RESOLVED, That all facilities which collect blood and
- 23 plasma for fractionation into plasma therapeutic proteins are
- 24 strongly encouraged to become certified under the IQPP
- 25 program, and processors which fractionate source plasma are
- 26 strongly encouraged to become certified under the QSEAL
- 27 program; and be it further
- 28 RESOLVED, That entities which collect plasma recovered
- 29 from whole blood are encouraged to implement a quality and
- 30 safety standards certification program comparable to QSEAL
- 31 and IQPP; and be it further

RESOLVED, That health care professionals and health plans
that purchase and/or provide plasma proteins for patient care
are encouraged to utilize therapeutics that employ rigorous
quality systems, as exemplified by the IQPP and QSEAL
certification programs, which are aimed at assuring the
highest quality and safety of plasma donations from which
plasma therapies are derived.